
-
Alnylam Pharmaceuticals NASDAQ:ALNY Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Location: 675 W Kendall St, Massachusetts, 02142-1168, US | Website: www.alnylam.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
34.59B
Cash
2.695B
Avg Qtr Burn
-2.078M
Short % of Float
2.04%
Insider Ownership
3.87%
Institutional Own.
96.36%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy | Approved Update | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | Approved Quarterly sales | |
OXLUMO® (lumasiran) Details Primary hyperoxaluria | Approved Quarterly sales | |
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis, Cardiomyopathy | Approved Quarterly sales | |
Leqvio® (inclisiran) Details Transthyretin amyloidosis, Atherosclerotic cardiovascular disease | Approved Quarterly sales | |
Qfitlia™ (fitusiran) Details Hemophilia | Approved Quarterly sales | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | sNDA Resubmission | |
Nucresiran (ALN-TTRsc04) Details Transthyretin amyloidosis | Phase 3 Initiation | |
Mivelsiran (ALN-APP) Details Cerebral Amyloid Angiopathy | Phase 2 Data readout | |
Zilebesiran (ALN-AGT) Details Metabolic disorder, Pulmonary arterial hypertension | Phase 2 Data readout | |
Elebsiran (ALN-HBV02 [VIR-2218] +/- VIR-3434) Details Hepatitis D, Hepatitis B | Phase 2 Data readout | |
Mivelsiran (ALN-APP) Details Alzheimer's disease | Phase 1 Update | |
ALN-HSD Details Non-alcoholic steatohepatitis | Phase 1 Update | |
ALN-PNP Details Non-alcoholic steatohepatitis | Phase 1 Update | |
ALN-KHK Details Type 2 diabetes | Phase 1a Data readout | |
OXLUMO® (lumasiran) Details Kidney disease | Failed Discontinued | |
ALN-XDH Details Arthritis, Chronic refractory gout | Failed Discontinued |